“This cohort patient study provides an invaluable blueprint to inform future treatment decision-making and support optimal use of romosozumab in clinical practice, both in Denmark and across Europe,” said Emmanuel Caeymaex, Executive Vice President, Immunology and U.S. Solutions at UCB. “The study findings enable us to understand the use of romosozumab as a treatment option in the real world and demonstrate its potential in closing the treatment gap for patients at high risk of fracture.”
The retrospective cohort study in Denmark showcased the significance of romosozumab in routine clinical practice, particularly among postmenopausal women at high fracture risk. Notably, patients in the romosozumab cohort had experienced hip and spine fractures prior to treatment, emphasizing the critical need for effective intervention.
Osteoporosis imposes a significant global burden, yet many remain untreated following fragility fractures. By leveraging real-world data, we’re advancing towards closing this treatment gap and improving patient care.
For further details, feel free to reach out to us. Let’s continue driving progress in osteoporosis management together!
